Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | 0.00% | 0.00% | -99.76% |
Apr. 02 | Motion for Asset Sale Approved for Biocept, Inc. | CI |
2023 | Biocept, Inc.(OTCPK:BIOC.Q) dropped from NASDAQ Composite Index | CI |
Financials (USD)
Sales 2021 | 61.25M | Sales 2022 | 25.86M | Capitalization | 9.04M |
---|---|---|---|---|---|
Net income 2021 | -2M | Net income 2022 | -32M | EV / Sales 2021 | 0.73 x |
Net cash position 2021 | 16.19M | Net cash position 2022 | 788K | EV / Sales 2022 | 0.32 x |
P/E ratio 2021 |
-18.9
x | P/E ratio 2022 |
-0.28
x | Employees | 50 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 100% |
Latest transcript on Biocept, Inc.
6 months | -99.98% | ||
Current year | -99.76% |
Managers | Title | Age | Since |
---|---|---|---|
Barbara Blouw
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Nathaniel Sweed
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Operating Officer | 60 | 22-03-07 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 0.0001 | 0.00% | 2 189 |
24-04-19 | 0.0001 | 0.00% | 5,074 |
24-04-17 | 0.0001 | +9,900.00% | 6,072 |
24-04-16 | 0.000001 | -99.00% | 100 |
Delayed Quote OTC Markets, April 19, 2024 at 03:55 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-99.76% | 262 | |
+0.80% | 12.66B | |
-17.03% | 7.04B | |
+1.89% | 5.39B | |
-2.51% | 4.45B | |
+2.03% | 4.32B | |
-50.32% | 3.31B | |
+6.90% | 2.6B | |
-16.08% | 2.01B | |
-2.30% | 1.67B |
- Stock Market
- Equities
- BIOCQ Stock